Formycon’s Keytruda Biosimilar Enters Phase I Clinical Trial

Phase III Study In NSCLC Patients Is Expected To Begin Shortly

 
• By Urtė Fultinavičiūtė
  
Formycon company logo
• Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin